When the Cost of His Asthma Inhaler Went Up $500, His Parents Claim He Couldn't Pay. Two Weeks Later He Was Dead at 22
Cole Schmidtknecht, 22, couldn't pay for his daily inhaler due to the “prohibitively expensive” price increase. Two weeks ...
Hosted on MSN3d
Balance Diet Helps Manage Asthma-Here's What You Should Eat
While there is no one-size-fits-all diet for asthma, research suggests that eating a balanced diet may help reduce symptoms ...
Too Old to Operate3d
Severe Asthma Trajectory Prior to Treatment Influences Outcomes
Pre-treatment disease trajectories in severe asthma impact treatment-related outcomes, according to a study by Johannes ...
Healio13d
Six-month asthma control score on mepolizumab predicts remission in eosinophilic asthma
Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was ...
The Lancet9d
Chronic obstructive pulmonary disease: new therapies and old needs
Chronic obstructive pulmonary disease (COPD) is a manifestation of structural violence, the process through which societies ...
pulmonologyadvisor6d
Rhinoconjunctivitis in Children With Asthma May Not Always Be Allergy Driven
Phenotyping children with asthma based on rhinoconjunctivitis symptoms shows that rhinoconjunctivitis may not always be allergy driven.
pharmaphorum13d
Stopwatch starts on reviews of GSK's long-acting asthma drug
Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...
Pharmabiz12d
GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP
GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...